ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Jun 4, 2013
ASCO Reveals That Big Pharma Is Alive
Some good news from Bristol-Myers Squibb, Merck, GlaxoSmithKline, and Amgen showed the promise of immunotherapies for cancer treatment.
Jan 24, 2013
Bristol-Myers Squibb Beats Estimates
Bristol-Myers is doing a decent job of navigating patent losses. We’re evaluating the firm for addition to the portfolio of our Dividend Growth Newsletter.
Jan 1, 2013
The Valuentum Dividend100 Publication; A Must-Have For Any Income Investor
This quarterly publication puts the top 100 high-quality, dividend-growth gems at your fingertips. We believe the Valuentum Dividend100 is a must-have for any income portfolio manager.
Dec 11, 2012
Inside AbbVie: A Look at a New Pharmaceutical Giant
Let's take a look at Abbott's new standalone business, AbbVie.
Oct 27, 2012
AstraZeneca Is Not Immune to Patent Cliff
AstraZeneca faced revenue and earnings pressure from the loss of exclusivity of Seroquel IR. Still, the firm boasts an impressive pipeline, and management reiterated its full-year earnings guidance.
Jul 2, 2012
Bristol-Myers Squibb and AstraZeneca Purchase Amylin
The two pharmaceutical companies will collaborate to commercialize the diabetes portfolio of Amylin. We think the deal is value neutral.
Jun 13, 2012
Johnson and Johnson’s Deal for Synthes Closes; Healthcare Spending Will Grow
We take a look at some recent developments in the healthcare industry.
Jun 4, 2012
Bristol-Myers Squibb Cancer Drug Shows Promise
A new drug that shrinks tumors in lung cancer patients exemplifies Bristol-Myers' aggressive cancer treatment pipeline. However, we think its stock is expensive at current levels.
Jul 11, 2011
Looking for a Pullback to Pick Up Johnson & Johnson's Shares
We think J&J's shares are fully-valued at this time, but we'd be looking to pick some up if the firm offered a dividend yield of 4%.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.